SML0650

Risedronate sodium

≥97% (HPLC)

• Synonyme(s) : P,P′-[1-Hydroxy-2-(3-pyridinyl)ethylidene]bis-phosphonic acid sodium, Sodium risedronate, [1-Hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic acid] monosodium salt
• Formule empirique (notation de Hill) : C₇H₁₀NO₇P₂ · Na
• Numéro CAS: 115436-72-1
• Poids moléculaire : 305.09
• UNSPSC Code: 41106300
• NACRES: NA.77
• Assay: ≥97% (HPLC)
• Form: powder

Propriétés

• Quality Segment: 100
• assay: ≥97% (HPLC)
• form: powder
• color: white to beige
• solubility: H₂O: 5 mg/mL, clear (warmed)
• storage temp.: room temp
• SMILES string: [Na+].[P](=O)([O-])(O)[C@]([P](=O)(O)O)(O)Cc1cnccc1
• InChI: 1S/C7H11NO7P2.Na/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);/q;+1/p-1
• InChI key: DRFDPXKCEWYIAW-UHFFFAOYSA-M

Description

Biochem/physiol Actions

Risedronate sodium is a bisphosphonate bone resorption inhibitor.

Risedronate sodium is a bisphosphonate bone resorption inhibitor. It has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent and is an inhibitor of farnesyl diphosphate (FPP) synthase, which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. Risedronate sodium has been used to treat postmenopausal osteoporosis and Paget′s disease.

Informations sur la sécurité

• Pictogrammes: GHS07
• Mot-clé: Warning
• Codes de danger: H302 + H312 + H332
• Mentions de précaution: P261 - P264 - P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312
• Hazard Classifications: Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral
• Classe de stockage: 11 - Combustible Solids
• Que se passe-t-il ?: WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable